Europe Cancer Immunotherapy Market Size & Outlook
Europe cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
Europe cancer immunotherapy market highlights
- The Europe cancer immunotherapy market generated a revenue of USD 35,535.6 million in 2023.
- The market is expected to grow at a CAGR of 8% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Spain is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 35,535.6 million |
| Market revenue in 2030 | USD 61,078.1 million |
| Growth rate | 8% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, Europe region accounted for 28.3% of the global cancer immunotherapy market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 59,131.5 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 65.28% in 2023. Horizon Databook has segmented the Europe cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Europe holds the second largest market share due to the presence of prominent research institutes and market players in this region. The growth of cancer immunotherapy market in this region can be attributed to increasing collaborations between European universities and oncology drug manufacturers.
Increasing number of initiatives being undertaken by governments and private organizations to create awareness about cancer diagnosis & treatment is expected to boost the growth of Europe cancer immunotherapy market during the forecast period.
The cancer immunotherapy market in Europe is expected to grow at a significant rate during the forecast period due to combined efforts of several government & private institutes, such as European Organization for Research and Treatment of Cancer (EORTC) and the European Medicines Agency (EMA), to develop a unique program focusing on multiple approaches in drug development.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe cancer immunotherapy market size, by country, 2018-2030 (US$M)
Europe Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
